Could a common antibiotic boost chemo for tough breast cancer?

NCT ID NCT04722978

Recruiting now Disease control Sponsor: Sun Yat-Sen University Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether adding the antibiotic moxifloxacin to standard chemotherapy (gemcitabine and carboplatin) helps people with metastatic triple-negative breast cancer live longer without their cancer growing. About 228 participants will receive either the antibiotic or a placebo alongside chemo. The goal is to see if this combination improves progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: moxifloxacin (an antibiotic) plus gemcitabine and carboplatin (standard chemotherapy)
What this could lead to: If it works, this could offer a new, affordable first-line treatment option for metastatic triple-negative breast cancer by boosting the effectiveness of standard chemotherapy.
What could go wrong: This is a phase 3 trial, but adding an antibiotic to chemo may not improve survival and could increase side effects like nausea or antibiotic resistance. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.